 |
8 Diseases |  |
0 Trials |
|
0 Trials |  |
36 News |  |
- PHOSPHATE BINDERS FOR PATIENTS WITH CHRONIC KIDNEY DISEASE UNDERGOING DIALYSIS: A NETWORK META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS (Focussed Oral Room 10) - May 4, 2023 - Abstract #ERAEDTA2023ERA_EDTA_1437;
Interventions and controls were the following: sevelamer-, bixalomer-, tenapanor-, iron- (ferric citrate, sucroferric oxyhydroxide), calcium-, magnesium-, lanthanum-, aluminium-, nicotinic acid-, and standard treatment or placebo). Our findings from SR based on NMA suggest that lanthanum may attenuate CACS and sevelamer may reduce the risk of all-cause mortality compared to calciumcontaining PBs in patients with CKD requiring dialysis.
- || Review, Journal: An update on phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a review of safety profiles. (Pubmed Central) - Aug 24, 2022
Although ferric citrate reduces erythropoiesis-stimulating agents and intravenous iron doses, its use requires monitoring of iron metabolic markers to avoid overload...However, increased pill burden and nonadherence to phosphate binders emerge as new problems. We expect that novel therapeutic strategies will be developed to resolve these issues.
- || Review, Journal: The Rising Risk of Chronic Kidney Disease (CKD) and How it is Dealt With: A Review of Current and Potential Phosphate Binders (PB). (Pubmed Central) - Apr 7, 2022
Nano-lanthanum hydroxide and SBR759 may have an interesting future as PBs. In conclusion, the development of new PBs should also take into consideration their potential to function as protection modifiers.
- || Tivicay (dolutegravir) / ViiV Healthcare
PK/PD data, Journal: Multivalent cation and polycation polymer preparations influence pharmacokinetics of dolutegravir via chelation-type drug interactions. (Pubmed Central) - Oct 22, 2021
This study examined how the pharmacokinetics of DTG are affected by co-administration with Al(OH), LaCO, and the polycation polymers bixalomer (Bxl) and sevelamer (Svl)...These comparisons also revealed a considerable reduction in the maximum concentration, suggesting that the interactions of these agents with DTG in the intestinal tract inhibit absorption of DTG. The above results demonstrate that Al(OH), LaCO, Bxl, and Svl affect the pharmacokinetics of DTG and indicate the need for caution when combining any of the above preparations with DTG.
- [VIRTUAL] Successful Treatment of Systemic Calcinosis in a Teenager on Hemodialysis () - Oct 17, 2021 - Abstract #KIDNEYWEEK2021KIDNEY_WEEK_2901;
Dialytic phosphate (P) clearance, and non-calcium(Ca), non-aluminum(Al) based binder use were maximized, using sevelamer and lanthanum carbonate...After 10 months, iv pamidronate was initiated to prevent further demineralization...Lanthanum is an effective metal Ca binder, but prolonged use may lead to accumulation and systemic deposition. The emergence of new P binders: ferric citrate, sucroferric oxyhydroxide, and bixalomer will offer exciting new treatment options.
- || Review, Journal: Phosphate binders in chronic kidney disease: an updated narrative review of recent data. (Pubmed Central) - Aug 20, 2021
For this narrative review a PubMed searched was undertaken to identify new publications on phosphate binders that had been published between January 2015 and July 2019. The present review summarizes this most recent information on dietary measures and their problems in treating hyperphosphatemia in CKD patients, overall effects of phosphate binders on cardiovascular mortality and morbidity, adherence to phosphate binder therapy as well as new data on specific aspects of the various phosphate binders on the market: calcium-containing phosphate binders, polymeric phosphate binders (sevelamer, bixalomer, colestilan), magnesium-containing phosphate binders, lanthanum carbonate, ferric citrate, sucroferric oxyhydroxide, and new compounds in development, in particular drugs targeting intestinal phosphate transporters.
- | Isentress (raltegravir) / Merck (MSD)
Journal: Concurrent administration with multivalent metal cation preparations or polycationic polymer preparations inhibits the absorption of raltegravir via its chelation. (Pubmed Central) - Jun 23, 2021
The present review summarizes this most recent information on dietary measures and their problems in treating hyperphosphatemia in CKD patients, overall effects of phosphate binders on cardiovascular mortality and morbidity, adherence to phosphate binder therapy as well as new data on specific aspects of the various phosphate binders on the market: calcium-containing phosphate binders, polymeric phosphate binders (sevelamer, bixalomer, colestilan), magnesium-containing phosphate binders, lanthanum carbonate, ferric citrate, sucroferric oxyhydroxide, and new compounds in development, in particular drugs targeting intestinal phosphate transporters. The interaction of RAL with Al(OH) , LaCO Bxl, or Svl can inhibit RAL absorption into the gastrointestinal tract, and thus, the multivalent metal cation and polycationic polymer are the modifying factors that can affect RAL pharmacokinetics.
- ||| Kiklin (bixalomer) / Astellas
Trial completion: Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer) (clinicaltrials.gov) - Jan 29, 2020
P=N/A, N=123, Completed, Sponsor: Astellas Pharma Inc
The interaction of RAL with Al(OH) , LaCO Bxl, or Svl can inhibit RAL absorption into the gastrointestinal tract, and thus, the multivalent metal cation and polycationic polymer are the modifying factors that can affect RAL pharmacokinetics. Active, not recruiting --> Completed
- | Renagel (sevelamer) / Sanofi, Kiklin (bixalomer) / Astellas, Fosrenol (lanthanum carbonate) / Takeda
Journal: Regional prescription surveillance of phosphate binders in the western Saitama area: the substantial role of ferric citrate hydrate in improving serum phosphorus levels and erythropoiesis. (Pubmed Central) - Dec 20, 2019
Active, not recruiting --> Completed This regional survey suggests that serum phosphorus is well managed and that FeC has the potential to reduce the serum phosphorus level relative to other PBs and to ameliorates anemia.
- | Renagel (sevelamer) / Sanofi, Kiklin (bixalomer) / Astellas, Fosrenol (lanthanum carbonate) / Takeda
Journal: Phosphate Binders Derived from Natural Ores Contain Many Kinds of Metallic Elements Besides Their Active Ingredient Metals. (Pubmed Central) - Mar 27, 2019
However, it should be emphasized that patients undergoing dialysis do not have a urinary excretion route and are administered many phosphate binder pills every day over a long period of time. In the future, pharmaceutical companies may have to disclose standard amounts and/or analytical values regarding the type and quantity of metallic elements in the final formulation or pharmaceutical bulk derived from natural ores.
- ||| Kiklin (bixalomer) / Astellas
Trial completion: Post-marketing Surveillance of Bixalomer in Patients With Pre-dialysis Chronic Kidney Disease (clinicaltrials.gov) - Jan 28, 2019
P=N/A, N=144, Completed, Sponsor: Astellas Pharma Inc
In the future, pharmaceutical companies may have to disclose standard amounts and/or analytical values regarding the type and quantity of metallic elements in the final formulation or pharmaceutical bulk derived from natural ores. Active, not recruiting --> Completed
- || Kiklin (bixalomer) / Astellas
Enrollment closed: Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer) (clinicaltrials.gov) - Jan 17, 2019
P=N/A, N=123, Active, not recruiting, Sponsor: Astellas Pharma Inc
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || Kiklin (bixalomer) / Astellas
Phase classification: Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer) (clinicaltrials.gov) - Apr 2, 2018
P, N=100, Recruiting, Sponsor: Astellas Pharma Inc
Recruiting --> Active, not recruiting Phase classification: P=N/A --> P
- || Kiklin (bixalomer) / Astellas
Enrollment closed, Enrollment change: Post-marketing Surveillance of Bixalomer in Patients With Pre-dialysis Chronic Kidney Disease (clinicaltrials.gov) - Aug 23, 2017
P=N/A, N=144, Active, not recruiting, Sponsor: Astellas Pharma Inc
Phase classification: P=N/A --> P Recruiting --> Active, not recruiting | N=100 --> 144
- ||| Kiklin (bixalomer) / Astellas
Trial completion: Post-marketing Surveillance of Kiklin Capsules in Hemodialysis Patients (clinicaltrials.gov) - Jan 30, 2017
P=N/A, N=1078, Completed, Sponsor: Astellas Pharma Inc
Recruiting --> Active, not recruiting | N=100 --> 144 Active, not recruiting --> Completed
- ||| Kiklin (bixalomer) / Astellas
Enrollment open: Post-marketing Surveillance of Bixalomer in Patients With Pre-dialysis Chronic Kidney Disease (clinicaltrials.gov) - Sep 30, 2016
P=N/A, N=100, Recruiting, Sponsor: Astellas Pharma Inc
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Kiklin (bixalomer) / Astellas
New trial: Post-marketing Surveillance of Bixalomer in Patients With Pre-dialysis Chronic Kidney Disease (clinicaltrials.gov) - Jun 20, 2016
P=N/A, N=100, Not yet recruiting, Sponsor: Astellas Pharma Inc
- ||||| Kiklin (bixalomer) / Astellas
New P2 trial: Dose Range-finding Study of ASP1585 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia (clinicaltrials.gov) - Apr 28, 2016
P2, N=73, Completed, Sponsor: Astellas Pharma Inc
- || Kiklin (bixalomer) / Astellas
Enrollment closed: Post-marketing Surveillance of Kiklin Capsules in Hemodialysis Patients (clinicaltrials.gov) - Mar 25, 2016
P=N/A, N=1078, Active, not recruiting, Sponsor: Astellas Pharma Inc
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Kiklin (bixalomer) / Astellas
New P1 trial: A Study of ASP1585 to Evaluate the Bioequivalence Between ASP1585 Granules and ASP1585 Capsules (clinicaltrials.gov) - Aug 24, 2015
P1, N=60, Completed, Sponsor: Astellas Pharma Inc
- ||||||| Kiklin (bixalomer) / Astellas
Trial completion: Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis (clinicaltrials.gov) - Jun 9, 2015
P3, N=105, Completed, Sponsor: Astellas Pharma Inc
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Kiklin (bixalomer) / Astellas
Enrollment closed, Trial primary completion date: Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis (clinicaltrials.gov) - Jul 16, 2014
P3, N=100, Active, not recruiting, Sponsor: Astellas Pharma Inc
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Apr 2015
- ||||||| Kiklin (bixalomer) / Astellas
Trial completion: A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis (clinicaltrials.gov) - Jul 16, 2014
P3, N=163, Completed, Sponsor: Astellas Pharma Inc
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Apr 2015 Active, not recruiting --> Completed
- ||||| Kiklin (bixalomer) / Astellas
Enrollment closed: A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis (clinicaltrials.gov) - Apr 10, 2014
P3, N=160, Active, not recruiting, Sponsor: Astellas Pharma Inc
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||| Kiklin (bixalomer) / Astellas
Enrollment open: Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis (clinicaltrials.gov) - Jul 7, 2013
P3, N=100, Recruiting, Sponsor: Astellas Pharma Inc
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||||||| Kiklin (bixalomer) / Astellas
New P3 trial: A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis (clinicaltrials.gov) - Dec 3, 2012
P3, N=160, Active, not recruiting, Sponsor: Astellas Pharma Inc
- |||||||||| Kiklin (bixalomer) / Astellas
New P3 trial: Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis (clinicaltrials.gov) - Dec 3, 2012
P3, N=100, Recruiting, Sponsor: Astellas Pharma Inc
- ||| Kiklin (bixalomer) / Astellas
Trial completion: A Phase 1 Multiple Dose Study to Compare the Effects of AMG 223 and Sevelamer HCL (Renagel (clinicaltrials.gov) - May 30, 2012
P1, N=66, Completed, Sponsor: Amgen Research (Munich) GmbH
Not yet recruiting --> Recruiting Active, not recruiting --> Completed